The European Commission has approved the use of ocriplasmin for treating vitreomacular traction (VMT) in the European Union.
![Ocriplasmin Gets EU Nod for Treating Vitreomacular Traction Ocriplasmin Gets EU Nod for Treating Vitreomacular Traction](https://images.medindia.net/health-images/1200_1000/terrorism.jpg)
The drug has been approved for treating VMT when it is associated with a macular hole with a diameter of 400 µm or less.
ThromboGenics will be paid €45 million by Alcon, a subsidiary unit of Novartis, with a similar payment to be made with the first sale of the drug. Around 250,000-300,000 patients in Europe are reported to suffer from VMT with the current treatment involving a ‘watchful process’ until the patient is eligible for surgery.
Source-Medindia